,
your personalized virtual assistant to find clinical trials. Go head, 
Thomas Gajewski, MD, PhD
University of Chicago HospitalChicago, Illinois - 60637 (773-834-9120) University of ChicagoChicago, Illinois - 60637 |
- CLINICAL TRIALS 3
- CONDITIONS1
- INTERVENTIONS4
- SINCE2006
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma
March 2008 - December 2011
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal Acral or Chronically Sun Damaged Melanoma
January 2009 - January 2012
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
July 2006 - July 2010
Melanoma
Nilotinib
Interferon Alpha
Kw2871
Imatinib
